Author: GlobeNewswire

2024 Research & Development Revenue of $30 Million Successful Results from the US Burn Validation Study On Track for Regulatory…

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical…

NEW YORK and LEAMINGTON, Ontario, March 27, 2025 (GLOBE NEWSWIRE) — Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY;…

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) — Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) is issuing this press…

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that…

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) — Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that…

Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom…

Encouraging efficacy data in a murine mesothelioma model with a selective A2B adenosine receptor antagonist given as a single agent…

• Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma…

Company to Host Conference Call Today, March 27, at 4:30pm ETBOCA RATON, Fla., March 27, 2025 (GLOBE NEWSWIRE) — INmune…